Samsung Bioepis Gets US Adalimumab Nod
Samsung Bioepis has become the first company to receive FDA approvals for biosimilars of all three first-generation anti-TNF biologics after gaining a nod for its Hadlima biosimilar adalimumab.
You may also be interested in...
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.